Concepedia

HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy

Jae Myoung Noh, Jihae Lee, Doo Ho Choi, Eun Yoon Cho, Seung Jae Huh, Won Park, Seok Jin Nam, Jeong Eon Lee, Won-Ho Kil

The Breast · 2013 · 11 citations · 17 references

Open access

Abstract

Adjuvant RT seems to counteract the negative effect of HER-2 overexpression in DCIS, while time to recurrence was relatively shorter.

References

17

Cancer Statistics, 2010

Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.3K citations · Full text

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Bernard Fisher, James J. Dignam, Norman Wolmark et al. · Journal of Clinical Oncology · 1998 · 888 citations

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

Irene Wapnir, James J. Dignam, Bernard Fisher et al. · JNCI Journal of the National Cancer Institute · 2011 · 774 citations · Full text